President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...

Finally, don't discount legal challenges to the president's tariffs. An argument could be made that pharmaceutical products ...

W hen Donald Trump’s tariffs are mentioned, you might recall his “Liberation Day” duties on uninhabited islands, his on-again ...

Johnson and Johnson beat Wall Street’s quarterly sales expectations and raised its full-year outlook, a show of confidence as ...

Despite former President Donald Trump’s threat of a 200% tariff on imported drugs during a cabinet meeting, pharmaceutical investors have shown surprisingly positive sentiment this week. Despite ...

Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong second-quarter sales of key ...

The opening salvo of second-quarter earnings calls this week came against President Donald Trump’s renewed calls for a tariff ...

A 200% tariff rate — even with a delay — will have a detrimental effect on drug prices and profit margins, analysts warn.

Drugmaker Swedish Orphan Biovitrum AB’s Chief Executive Officer Guido Oelkers said he doesn’t think tariff threats on the ...

Already late with carrying out his administration's prior threats around pharmaceutical tariffs, President Donald Trump has ...

Despite the threat of a 200% tariff, most pharma stocks remained stable. US President Donald Trump’s 200% tariff threat on the pharmaceutical industry is a “shock” that will reverberate through global ...

Trump’s threat to slap a 200% tariff on pharmaceutical imports, made offhandedly at a cabinet meeting, has sparked a selloff in some drug stocks, but analysts say the number may be more political ...